Cancer chemotherapy and radiotherapy are designed to kill cancer cells mostly by inducing DNA damage. DNA damage is normally recognized and repaired by the intrinsic DNA damage response machinery. If the damaged lesions are successfully repaired, the cells will survive. In order to specifically and effectively kill cancer cells by therapies that induce DNA damage, it is important to take advantage of specific abnormalities in the DNA damage response machinery that are present in cancer cells but not in normal cells. Such properties of cancer cells can provide biomarkers or targets for sensitization. For example, defects or upregulation of the specific pathways that recognize or repair specific types of DNA damage can serve as biomarkers of favorable or poor response to therapies that induce such types of DNA damage. Inhibition of a DNA damage response pathway may enhance the therapeutic effects in combination with the DNA-damaging agents. Moreover, it may also be useful as a monotherapy when it achieves synthetic lethality, in which inhibition of a complementary DNA damage response pathway selectively kills cancer cells that have a defect in a particular DNA repair pathway. The most striking application of this strategy is the treatment of cancers deficient in homologous recombination by poly(ADP-ribose) polymerase inhibitors. In this review, we describe the impact of targeting the cancer-specific aberrations in the DNA damage response by explaining how these treatment strategies are currently being evaluated in preclinical or clinical trials.
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T he genome DNA is constantly exposed to various genotoxic insults. Among the variety of types of DNA damage, the most deleterious is the DNA double-strand break (DSB).
(1) Double-strand breaks can be generated by endogenous sources such as reactive oxygen species produced during cellular metabolic processes and replication-associated errors, as well as by exogenous sources including ionizing radiation and chemotherapeutic agents. Double-strand breaks are also generated in a programmed manner during meiosis and during the V(D)J recombination and class switch recombination required for the development of lymphocytes. If left unrepaired, DSBs can result in cell death. If accurately repaired, DSBs can result in survival of cells with no adverse effects. If insufficiently or inaccurately repaired, DSBs can result in survival of cells showing genomic alterations that may contribute to tumor development.
(2) In order to maintain genomic integrity, cells have evolved a well coordinated network of signaling cascades, termed the DNA damage response, to sense and transmit the damage signals to effector proteins, and induce cellular responses including cell cycle arrest, activation of DNA repair pathways, and cell death (Fig. 1 ).
(1)
Cancer chemotherapeutic agents and radiotherapy exert their cytotoxic effects by inducing DNA DSBs. As cancer cells often have specific abnormalities in the DNA damage response, therapeutic strategies based on such properties of cancer cells have been developed. Several inhibitors that block specific DNA damage responses or repair proteins have been tried not only as sensitizing agents in combination with DNAdamaging agents but also as single agents against cancers with defects in particular DNA repair pathways. The most prominent example of the latter is the killing effect of poly (ADP-ribose) polymerase (PARP) inhibitors on BRCA1-or BRCA2-defective tumors, which takes advantage of the defects in DNA repair in cancer cells. (3) In this review, we will first outline the mechanism of the DNA damage response. Next, we will describe the aberrations in DNA damage responses in human cancers. Finally, we will explain how different DNA damage response pathways can be targeted for cancer therapy.
Mechanism of DNA Damage Response
DNA-damaging agents induce various types of DNA damage including modification of bases, intrastrand crosslinks, interstrand crosslinks (ICL), DNA-protein crosslinks, single-strand breaks (SSBs), and DSBs. Each type of DNA damage is recognized and processed by proteins involved in the DNA damage response (Fig. 1) .
In response to DSBs, the MRE11-RAD50-NBS1 (MRN) complex senses and binds to DSB sites, and recruits and activates the ataxia telangiectasia mutated (ATM) kinase through its autophosphorylation.
(4,5) Once activated, ATM phosphorylates a large number of downstream proteins.
Phosphorylation of Chk2 induces phosphorylation of the protein phosphatase CDC25A, leading to cell cycle arrest. Phosphorylation of BRCA1 leads to DSB repair as well as cell cycle arrest in the S phase, whereas activation of p53 triggers cell cycle arrest in the G 1 phase or cell death. In the initiation of the response to SSBs or DNA replication fork collapse, the ataxia telangiectasia and Rad3-related (ATR) kinase is activated and recruited to the sites of DNA damage. (7) ATR phosphorylates and activates Chk1, (8) which plays a role in the S and G 2 ⁄ M cell checkpoints by regulating the stability of the CDC25 phosphatases. Activation of the 53BP1 protein, a mediator of the DNA damage response, contributes to the choice of the DSB repair pathways by promoting non-homologous end joining (NHEJ). (9) The DNA repair pathways can either work independently or coordinately to repair different types of DNA damage (Fig. 1) . Double-strand breaks are predominantly repaired by either NHEJ or homologous recombination (HR). (10) Nonhomologous end joining is an error-prone repair pathway that is mediated by the direct joining of the two broken ends. (10) Factors involved in NHEJ include the Ku70 ⁄ Ku80 complex, DNA-PK catalytic subunit (DNA-PKcs), the Artemis nuclease, XLF, XRCC4, and DNA ligase IV. Homologous recombination is an error-free repair pathway that requires a nondamaged sister chromatid to serve as a template for repair (Fig. 2) . (10) Factors involved in HR include the MRN complex, CtIP, replication protein A (RPA), BRCA1, PALB2, BRCA2, and RAD51. In addition to NHEJ and HR, an alternative form of NHEJ, namely, alt-NHEJ, is also involved in DSB repair. (11) It exhibits a slower process than the classical NHEJ and can catalyze the joining of unrelated DNA molecules, leading to the formation of translocations as well as large deletions and other sequence alterations at the junction. Factors involved in this pathway include PARP-1, XRCC1, DNA ligase IIIa, polynucleotide kinase, and Flap endonuclease 1.
Single-strand breaks and subtle changes to DNAs are repaired using base-excision repair (BER) proteins, (12) which include PARP-1, XRCC1, DNA ligase IIIa, and apurinic ⁄ apyrimidinic endonuclease (APE1). Bulky DNA lesions such as pyrimidine dimers caused by UV irradiation are processed by the nucleotide excision repair (NER) pathway, (13) which requires the excision repair cross-complementing protein 1 (ERCC1). Base mismatches arising as a result of replication errors can be repaired by the mismatch repair pathway. (14) In the repair of ICL, ubiquitin-mediated activation of the Fanconi anemia (FA) pathway plays a key role. (15) The FA pathway is constituted by at least 15 FA gene products, whose germline defects result in FA, a cancer predisposition syndrome. Fig. 1 . Overview of the diverse spectrum of DNA damage and the DNA damage response. The major repair pathways and key proteins used to process each type of damage are shown. In non-homologous end-joining (NHEJ), the Ku70 ⁄ Ku80 complex binds to the DNA double-strand break ends and recruits the other indicated components. In base-excision repair (BER), poly(ADP-ribose) polymerase-1 (PARP-1) detects and binds to single-strand breaks and ensures accumulation of other repair factors at the breaks. Single-strand breaks containing modified DNA ends are recognized by damage-specific proteins such as apurinic ⁄ apyrimidinic endonuclease (APE1), which subsequently recruits Polb and XRCC1-DNA ligase IIIa to accomplish the repair. All the molecules indicated here are aberrated in sporadic cancers. The proteins targeted for cancer therapy in the present clinical trials are marked with red asterisks. alt-NHEJ, alternative NHEJ; ATM, ataxia telangiectasia mutated; ATR, ataxia telangiectasia and Rad3-related; FA, Fanconi anemia; HR, homologous recombination; MGMT, O 6 -methylguanine-DNA methyltransferase; MMR, mismatch repair; MRN, MRE11-RAD50-NBS1; NER, nucleotide excision repair; TLS, translesion synthesis.
Activation of the FA core complex, which is comprised of eight FA proteins (FANCA ⁄ B ⁄ C ⁄ E ⁄ F ⁄ G ⁄ L ⁄ M) and associated proteins, leads to monoubiquitination of FANCD2 and FANCDI, which subsequently coordinates three critical DNA repair processes, including nucleolytic incision by XPF-ERCC1 and SLX4 endonucleases, translesion DNA synthesis, and HR.
Aberrations in DNA Damage Responses in Human Cancers
In sporadic cancers, both activation and inactivation of the DNA damage response are found in various cancers, as summarized in Table 1 .
Regarding activation of the DNA damage response proteins, increased autophosphorylation of ATM and ATM-dependent phosphorylation of Chk2 are reported in early-stage tumors, suggesting that the DNA damage response may serve as a barrier to the malignant progression of tumors. (16, 17) In contrast, a recent study reports that ATM is hyperactive in late-stage breast tumor tissues, suggesting that the ATM-mediated DNA damage response also plays a role in tumor progression and metastasis. (18) Increased expression of NBS1, RAD50, Chk1, Chk2, CDC25A, CDC25B, and CDC25C are also reported. (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) DNA-PK catalytic subunit is reported to be upregulated in radiation-resistant tumors or in tumors with poor survival. (29, 30) Overexpression of RAD51, BRCA1, ERCC1, APE1, and PARP1 is also observed in various cancers and is associated with resistance to chemotherapy. (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) However, inactivation of DNA damage response proteins is also observed in various cancers. The p53 gene is one of the most frequently mutated genes in human sporadic cancers. Although the reported frequencies of p53 mutation vary among the types of cancer, it is estimated that more than half of cancers might have inactivated p53 due to mutations, deletion, loss of heterozygosity of the gene, or decreased expression. (47, 48) Although inactivating mutations in ATM, BRCA1, or BRCA2 are less frequent than those in the p53 gene, (49) (50) (51) (52) (53) decreased expression of ATM, the MRN complex, Chk2, RAD51, BRCA1, BRCA2, and ERCC1 is frequently observed, suggesting that aberration of the DNA damage response is common in sporadic cancers. (19, 22, 23, 26, (54) (55) (56) (57) (58) (59) (60) (61) (62) Promoter hypermethylation of the BRCA1 gene is frequently observed and may be one of the predominant mechanisms for deregulation of the BRCA1 gene. (62) Furthermore, our group reported the functional inactivation of BRCA2 in cancer cells aberrantly expressing SYCP3, a cancertestis antigen. (63) Disruption of the FA pathway resulting from mutations or decreases or loss of expression due to promoter hypermethylation has been also described in various cancers. (64, 65) As described above, both activation and inactivation of the DNA damage response are observed in cancers, and are expected to determine important properties of the DNA damage response machinery present in each cancer. The status of BRCA has been adopted as an important condition factor in current clinical trials, however, the status of other DNA damage response proteins have not yet been translated into clinical trials. In the next section, we will introduce various approaches for taking advantage of these cancer-specific properties of the DNA damage response in cancer therapy. Because the efficacy of cancer chemotherapy and radiotherapy relies on generation of DNA damage that will be recognized and repaired by intrinsic DNA repair pathways, aberrant expression of a particular DNA damage response protein should be a biomarker of resistance or favorable response to therapies that induce the corresponding types of DNA damage. (66) For example, patients with surgically treated nonsmall-cell lung cancer whose tumors lacked expression of ERCC1 were shown to benefit from cisplatin-based adjuvant chemotherapy in a clinical study. (38) Another example is the case of RAD51, whose expression can serve as a marker of cisplatin resistance in non-small-cell lung cancer, which is consistent with the role of HR in the repair of ICL. (31) In contrast, many inhibitors of the DNA damage response have been developed and some of them have been tested for their potential to enhance DNA damage-induced tumor cell killing in preclinical studies and clinical trials (Tables 2 and 3) .
Inhibitors of ATM ⁄ ATR and the MRN complex. As ATM and the MRN complex play central roles as sensors or mediators in the DNA damage response, these molecules have been considered to be promising targets for radiosensitization or chemosensitization. (67) Several promising ATM inhibitors have been developed (Table 2) . KU55933, the first specific inhibitor of ATM, inhibits radiation-induced ATM-dependent phosphorylation events and sensitizes cancer cells to radiation and Early steps of homologous recombination. First, the DNA double-strand break is sensed by the MRE11-RAD50-NBS1 (MRN) complex, which subsequently recruits and activates the ataxia telangiectasia mutated (ATM) kinase. Then, the DNA ends are resected by the MRN complex and CtIP, resulting in generation of 3 0 single-stranded DNA (ssDNA) overhangs on both sides of the break. These overhangs are coated and stabilized by replication protein A (RPA). Next, BRCA2, which forms the BRCA1-PALB2-BRCA2 complex, directly binds RAD51 and recruits it to the double-stranded DNA-ssDNA junction, and promotes the loading of RAD51 onto ssDNA. This step is followed by displacement of RPA from ssDNA ends and assembly of the RAD51-ssDNA filament, which is mediated by BRCA2, leading to strand invasion into an undamaged homologous DNA template. All the molecules indicated here are aberrated in sporadic cancers. None of the proteins indicated here are targeted for cancer therapy in the present clinical trials. P, phosphorylation. (29, 30) topoisomerase inhibitors. (67) KU60019, an improved analog of KU55933, inhibits the DNA damage response and effectively radiosensitizes human glioma cells. (68) Mirin is an inhibitor of the MRN complex, which prevents MRN-dependent activation of ATM without affecting ATM protein kinase activity and inhibits MRE11-associated exonuclease activity. (67) Telomelysin is another inhibitor that inhibits the MRN complex through the adenoviral E1B-55 kDa protein. (67) The therapeutic outcomes of these agents remain to be tested in clinical trials. Although the long search for selective inhibitors of ATR has not yet paid off, schisandrin B was recently identified as a moderate selective ATR inhibitor, although it will also affect ATM at high concentrations. (69) Recently, two novel ATR inhibitors, NU6027 and VE-821, were also shown to sensitize cells to a variety of DNA-damaging agents in preclinical studies. (70, 71) Inhibitors of Chk1 ⁄ Chk2 and CDC25. As the triggering of cell cycle checkpoints is crucial in the DNA damage response, these checkpoints have also been widely investigated as a potential target for cancer therapy (Table 3) . (72) Among the inhibitors for Chk1 and ⁄ or Chk2, UCN-01 was the first to enter clinical trials, but it was discontinued due to toxicities such as symptomatic hypotension and neutropenia and a lack of convincing efficacy after phase II trials. (72) Other Chk1 ⁄ Chk2 inhibitors with improved specificities, including XL844 and AZD7762, also entered clinical trials but failed to achieve a good response. (72) The selective Chk1 inhibitor SCH900776 has been used in phase I trials for acute leukemia in combination with cytarabine and for solid tumors in combination with gemcitabine, and showed some partial responses and stable disease. (72) The Chk1 inhibitor LY2603618 and the dual Chk1 ⁄ Chk2 inhibitor LY2606368 are also currently being tested in early clinical trials. CDC25 phosphatases, the key factors in cyclin-dependent kinase activation crucial for cell cycle regulation, are also considered to represent promising novel targets in cancer therapy. CDC25 inhibitors have also been developed, and some have entered into clinical trials, although the clinical data is limited. (73) Inhibition of NHEJ by DNA-PK inhibitors. Regarding NHEJ, inhibitors of DNA-PK, including NU7026 and NU7441, were found to induce extreme sensitivity to ionizing radiation as well as DNA-damaging agents in preclinical studies (Table 2) . (74) However, the therapeutic efficacy of DNA-PK inhibitors depends on the expression levels of DNA-PK in cancer cells versus normal cells, and their clinical application is currently restricted because of their toxicity to normal cells. The dual mTOR and DNA-PKcs inhibitor CC-115 is undergoing early clinical evaluation (Table 3) . KU-0060648 is a potent dual inhibitor of DNA-PK and PI-3K, which has recently been reported to enhance etoposide and doxorubicin cytotoxicity (Table 2) . (75) Inhibition of NHEJ or alt-NHEJ by DNA ligase inhibitors. DNA ligases are required for both NHEJ and alt-NHEJ pathways as well as other DNA repair pathways such as BER and NER. Small molecule inhibitors of human DNA ligases have been identified and shown to be cytotoxic and also to enhance the cytotoxicity of DNA-damaging agents. SCR7 is an inhibitor of DNA ligase IV, which is involved in the NHEJ pathway. SCR7 reduces cell proliferation in a DNA ligase IV-dependent manner and increases the tumor-inhibitory effects of agents that cause DSBs. (76) L67 is an inhibitor of DNA ligases I and IIIa, which are involved in the alt-NHEJ pathway as well as BER and NER. The levels of the alt-NHEJ proteins such as DNA ligase IIIa and WRN are reported to be elevated in BCR-ABL-positive CML cell lines, (77) so inhibition of alt-NHEJ factors may be an additional therapeutic approach in BCR-ABL-positive CML, which is usually treated by tyrosine kinase inhibitors. Indeed, CML cell lines with increased alt-NHEJ were shown to be hypersensitive to the combination of L67 and PARP inhibitor. (78) Inhibitors of RAD51 and tyrosine kinases regulating HR. With respect to HR, there are currently few inhibitors that directly target HR proteins. Along with the RAD51 inhibitors that were recently identified (Table 2) , (79) the molecules that indirectly regulate HR may also be candidate targets for inhibiting HR. For example, the non-receptor tyrosine kinase c-Abl is activated by ATM in response to DNA damage, and subsequently phosphorylates RAD51. (80) Oncogenic fusion tyrosine kinases, such as BCR-ABL, TEL-ABL, TEL-JAK2, TEL-PDGFbR, and NPM-ALK, enhance the expression levels and ⁄ or tyrosine phosphorylation of RAD51. (81, 82) From these findings, inhibitors of oncogenic tyrosine kinases are expected to sensitize cancer cells to DNA-damaging agents. Consistent with this hypothesis, treatments with the tyrosine inhibitor imatinib have been shown to enhance sensitivity to DNA crosslinking agents and ionizing radiation in cancer cells. (81) Furthermore, targeting RAD51 was shown to overcome imatinib resistance in CML cells. (83) Inhibitors of histone deacetylases, heat shock protein 90, and DSB repair. Histone deacetylases (HDACs) are powerful regulators of the stability of the genome, and many HDAC inhibitors are shown to downregulate multiple components of the DNA damage response and repair, including HR, NHEJ, the MRN complex, and ATM. (84) Thus, the use of HDAC inhibitors in combination with DNA-damaging agents may be an area of great interest with potential clinical utility. The HDAC inhibitor PCI-24781 caused increased apoptosis by inhibiting RAD51-mediated HR when used in combination with the PARP inhibitor PJ34 in a preclinical study. (85) The inhibitor of heat shock protein 90, 17-allylamino-17-demethoxygeldanamycin, radiosensitizes human tumor cell lines by inhibiting RAD51-mediated HR. (86) Curcumin is a natural product that has been tested for its chemosensitizing potential, and sensitizes cancer cells to PARP inhibitors by inhibiting NHEJ, HR, and the DNA damage checkpoint. (87) Inhibitors of PARP and APE1 in combination with DNA-damaging agents. Inhibitors of PARP, which inhibit the BER and SSB repair pathways, are the most advanced and promising drugs that target DNA repair. (88) A number of clinical trials using PARP inhibitors are currently underway (Table 3) . Inhibitors of PARP were first tried in combination with DNA-damaging agents. Some clinical responses were observed in the phase I and II trials of the PARP inhibitor rucaparib in combination with temozolomide. (89, 90) Further clinical trials of PARP inhibitors have been carried out in combination with various DNAdamaging agents and ⁄ or ionizing radiation (Table 3) . Inhibitors of another BER protein APE1 are also being tested in combination with DNA-damaging agents in clinical trials (Table 3) .
Using PARP inhibitors as single agents in BRCA-deficient cancers based on the principle of synthetic lethality. In 2005, PARP inhibitors were shown to selectively inhibit the growth of cells with defects in either the BRCA1 or BRCA2 genes, suggesting a new use of PARP inhibitors as single agents. (91, 92) A possible explanation for this lethality is as follows. The cancer cells with defects in the BRCA gene are defective in HR, as the wild-type BRCA allele is absolutely lost. However, HR is intact in normal cells of the same patients who carry one wildtype BRCA allele and one mutant BRCA allele. Inhibition of PARP1 results in the accumulation of SSBs, which are converted to lethal DSBs that require HR for their repair. Although such lesions would be repaired by HR in normal cells, they are not repaired in BRCA1-or BRCA2-deficient cancer cells because these cells are defective in HR repair, and thus the tumor cells are led to death. This concept is termed synthetic lethality, namely, the process by which defects in two different genes or pathways together result in cell death while defects in one of the two different genes or pathways do not affect viability (Fig. 3) .
(3) This attractive new therapeutic strategy based on the principle of synthetic lethality relies on the frequent defects in the DNA damage response observed in cancer as summarized in the previous chapter and Table 1 , in which alternative DNA damage response pathways may be activated to allow cancer cells to survive in the presence of genotoxic stress. Because this strategy targets the cancer-specific aberrations in the DNA damage response, it will cause few or no toxicities on normal cells. The first report of a clinical trial of a PARP inhibitor as a single agent in patients with BRCA mutations was the phase I study of the oral PARP inhibitor olaparib. (93) It established the safety of olaparib as a single agent, and good responses were observed in patients with BRCA-mutated breast, ovarian, or prostate tumors. In subsequent phase II studies, approximately one-third of the patients with breast or ovarian cancer with germline BRCA mutations showed a favorable response to the drug with no severe toxicities. (94) Several other PARP inhibitors are currently being investigated in patients with germline BRCA mutations as single agents (Table 3) . It is likely that PARP inhibitors have significant benefit to at least a subpopulation of cancer patients with defects in BRCA-mediated HR pathways.
Using PARP inhibitors as single agents in cancers with no BRCA mutations. The potential for PARP inhibitors as single agents has also been tested in clinical trials of cancers with no germline BRCA mutations, such as high-grade serous ovarian cancers and triple-negative breast cancers. (95) Inhibitors of PARP were also effective in a subset of cancers with no germline BRCA mutations, suggesting that there may be a subset of sporadic cancers that show features of "BRCAness," which may show good response to PARP inhibitors. (96) Indeed, cancer cells expressing the cancer-testis antigen SYCP3, in which BRCA2 is functionally inactivated, as described above, show extreme hypersensitivity to a PARP inhibitor. (63) Defects in other HR-related proteins such as RAD51, RAD54, and RPA also confer selective sensitivity to PARP inhibition. (97) Moreover, defects in the DNA damage response proteins, such as NBS1, MRE11, ATR, ATM, For current status and information of clinical trials, refer to http://clinicaltrials.gov/, a service of the US National Institutes of Health. NSCLC, nonsmall-cell lung cancer.
FANCD2, FANCA, FANCC, Chk1, Chk2, and ERCC1, also confer selective sensitivity to PARP inhibition. (97, 98) Exploitation of other synthetic lethalities by DNA damage response. Taking advantage of the dysregulated DNA damage response in cancer using the synthetic lethality approach may be one of the most promising prospects for the future of cancer treatment. From this point of view, many efforts have been made to identify defects of two different DNA damage response genes or pathways that are synthetically lethal when combined. For example, ATM inhibition is shown to be synthetically lethal with FA pathway deficiency. (99) The suggested explanation for this lethality is as follows. The FA pathway-deficient cancer cells are defective in the repair of DNA replication fork stalling, which is normally repaired by ATR and the FA pathway. In FA pathway-deficient conditions, the stalled fork will collapse and form a DSB that will alternatively activate an ATM-dependent DNA damage response. Inhibition of ATM in such FA pathwaydeficient cells will leave no alternative mechanism for repair, leading to cell death. The FA pathway-deficient cells are also hypersensitive to Chk1 silencing, (100) which may be explained by the hyperdependence of the FA pathway-deficient cells on G 2 ⁄ M checkpoint activation mediated by Chk1 for viability. Because defects in the FA pathway are frequently observed in a number of different types of cancer (Table 1) , (64, 65) the use of ATM inhibitors or Chk1 inhibitors in FA pathway-deficient tumors will be a promising approach that should be evaluated in clinical trials in the future. In another example, RAD54B deficiency is shown to be synthetically lethal in cells with reduced Flap endonuclease 1 expression, but the mechanisms of this lethality remain to be elucidated. (101) Recently, inhibition of APE1 was shown to be synthetically lethal in BRCA-and ATM-deficient cells, presenting a novel model for APE inhibition as a synthetic lethal strategy in cells deficient in DSB repair. (102) Briefly, APE1 inhibition leads to AP site accumulation and results in indirect generation of SSBs that are eventually converted to toxic DSBs, which cannot be repaired in cells deficient in DSB repair. The APE1 inhibitors are being tested in combination with DNA-damaging agents in current clinical trials, and they may be evaluated further as a synthetic lethal strategy. More recently, inactivation of the HR protein RAD52 was shown to be synthetically lethal with deficiencies in BRCA2, BRCA1, and PALB2. (103, 104) This lethal effect may be due to the loss of RAD51-dependent HR function mediated by the BRCA1-PALB2-BRCA2 complex, because human RAD52 is suggested to function in an independent and alternative repair pathway of RAD51-dependent HR when deficiencies exist in BRCA1, PALB2, or BRCA2. As no inactivating mutations of RAD52 have been documented in human sporadic cancers, inhibition of RAD52 could be an attractive strategy for improving cancer therapy in the BRCA-or PALB2-defective subgroup of cancers. Although no inhibitors of RAD52 have been developed yet, it would be of great interest to assess the effects of inhibition of RAD52 on cancer-specific killing of the cancers with "BRCAness" profiles and compare them with those of PARP inhibitors in future clinical trials. There might be additional synthetic lethalities to be discovered and exploited in future.
Current Limitations and Future Perspectives
Although the data from clinical trials of the inhibitors of DNA damage response, including PARP inhibitors, seem encouraging, we should note that the use of PARP inhibitors also faces significant limitations.
The first limitation is the evolution of resistance. In the case of using PARP inhibitors in cancer cells carrying mutations in BRCA1 or BRCA2, the drug resistance can be caused by secondary mutations in the BRCA1 or BRCA2 gene that restore the open reading frame of the gene and enable the generation of functional BRCA proteins possessing the ability to repair DNA damage caused by PARP inhibitors. (105) (106) (107) Other suggested mechanisms underlying the resistance to PARP inhibitors include the loss of 53BP1 expression in BRCA-deficient cells and the upregulation of genes that encode P-glycoprotein efflux pumps, (108) (109) (110) (111) although the importance of these factors in clinical resistance to PARP inhibitors has not been elucidated. In future clinical trials, it would be desirable to periodically monitor the sequences of BRCA1 and BRCA2 and the expression levels of the key proteins such as 53BP1 or P-glycoprotein efflux pumps.
The second limitation is the lack of reliable biomarkers of response or resistance to the inhibitors. There is a pressing need to identify biomarkers to predict the response to the inhibitors. Regarding the sensitivities to PARP inhibitors, elevated levels of PARP and CDK12 deficiency are suggested to be possible biomarkers for favorable responses. (45, 112) We should also keep in mind that many factors might affect the DNA damage response and take into account the complexity of the networks regulating DNA repair. For instance, most cancer cells grow under hypoxia, a condition that activates hypoxia inducible factor-1 (HIF-1). Because HIF-1 contributes to therapy resistance, it is considered an attractive target molecule for cancer therapy. Diverse functional interactions between HIF-1 and the DNA damage response have also been described, (113) so the efficacy of the combination of HIF-1 inhibitors and inhibitors of the DNA damage response proteins should be examined in the future.
Conclusions
Defects or upregulation of the proteins involved in DNA damage response and repair are common in cancers, and may be induced by both genetic and epigenetic causes. Inhibition of the DNA damage response proteins can be used to enhance chemotherapy and radiotherapy, and also to selectively kill cancer cells showing deficiencies in particular DNA repair pathway(s) based on the principle of synthetic lethality. Inhibition of PARP in BRCA-defective cancers seemed effective in early clinical trials. Better understanding of the basic biology underlying the DNA damage response and the mechanisms responsible for its dysregulation in cancer will provide exciting opportunities for new and efficient cancer therapy targeting the DNA damage response.
